ST-segment elevation myocardial infarction (STEMI) is a major cause of morbidity and mortality worldwide. In spite of decrease in acute and long-term mortality following STEMI in parallel with more use of reperfusion therapy, such as primary percutaneous coronary intervention (PPCI), modern antithrombotic therapy, and secondary prevention, mortality remains considerable. Reduced EF is a well-known predictor of increased short and long term major adverse cardiovascular events MACE :( heart failure, stroke and death)
Full Title of Study: “The Role of Two- Dimensional Speckle Tracking Echocardiography in Prediction of Remodeling and Major Adverse Cardiovascular Events in ST Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention”
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: September 2021
- Procedure: 2D speckle tracking echocardiography
- Global and segmental strain and strain rate in longitudinal and circumferential directions will be detected after PPCI; before discharge. The LV circumferential strains and strain rates will be determined from the short-axis views at the basal, middle, and apical levels, and longitudinal strains and strain rates will be determined from the apical 2-, 3-, and 4-chamber views of the LV. Segmental longitudinal strains equal to -15% or closer to 0 will be considered abnormal (injured segments). The average segmental longitudinal strain and strain rate of the abnormal segments is defined as the injury longitudinal strain (InjLS) and injury longitudinal systolic strain rate (InjLSRs).
Arms, Groups and Cohorts
- Study group
- ST elevation myocardial infarction (STEMI) patients after primary percutaneous coronary intervention who will be followed up in Assiut University hospital.
Clinical Trial Outcome Measures
- The Incidence of major adverse cardiovascular events
- Time Frame: 1 year
- the rate of Acute coronary syndrome, Heart failure, Stroke and all-cause mortality
Participating in This Clinical Trial
- ST elevation myocardial infarction patients after primary percutaneous coronary intervention
- Previous myocardial infarction.
- Sever or haemodynamically significant (associated with chamber dilation) valvular heart diseases.
- Previous heart failure.
- Previous cerebrovascular strokes.
- Atrial fibrillation.
- Severe comorbidities as severe renal impairment, hepatic or respiratory failure.
- Bad equality views which affects accurate speckle tracking imaging.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 90 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Assiut University
- Provider of Information About this Clinical Study
- Principal Investigator: Waleed Rafat Rasmy, Principal investigator – Assiut University
- Overall Official(s)
- Hatem Helmy, MD, Study Director, Assiut University
- Overall Contact(s)
- Aly Tohamy, MD, 01006258877, Ali.email@example.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.